Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

1. Age 18-75

2. Histologically or cytologically confirmed resectable squamous-cell esophageal cancer ( cT1-2N+/ cT3-4aN0-3M0)

3. Eastern Cooperative Oncology Group (ECOG) status 0-1

4. Signed written informed consent prior to the implementation of any trial-related rocedures

5. Adequate organ function, evidenced by laboratory results with no contraindications to chemotherapy Absolute neutrophil count ≥ 1,500 х109/l Thrombocytes ≥ 100 х 109/l Hemoglobin ≥ 90 mg/l Creatinine ≤ 1.5 x ULN or creatinine clearance (calculated using the Cockcroft-Gault formula) ≥40 mL/min Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5 x upper limit of normal (ULN) Alkaline phosphatase (ALP) > 5 x ULN Bilirubin > 1.5 х ULN

1. Patients diagnosed with any other malignant tumor

2. Patients at risk for tracheoesophageal fistula or aortoesophageal fistula

3. Have received prior therapy with: chemotherapy, radiation therapy,immune checkpoint inhibitor

4. Insufficient caloric and/or fluid intake despite consultation with a dietitian and/or tube feeding

5. Have an active infection requiring systemic therapy that has not resolved 3 days (simple infection, such as cystitis) to 7 days (severe infection, such as pyelonephritis) before the first dose of trial treatment

6. Patients who cannot tolerate chemoradiotherapy or surgery due to severe cardiac, lung dysfunction

7. A history of interstitial lung disease or non-infectious pneumonia

8. Active autoimmune disease with systemic therapy (ie, use of disease modifiers, corticosteroids, or immunosuppressive drugs) in the past 2 years

9. Known history of human immunodeficiency virus (HIV) infection (i.e., positive for HIV 1/2 antibody) and various viral hepatitis infections

10. Patients who have received allogeneic stem cell or solid organ transplantation

11. Women during pregnancy or lactation